Holen Sie sich die Stockscreener-App
26.55
0.23%
0.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$26.49
Offen:
$26.42
24-Stunden-Volumen:
1.59M
Relative Volume:
0.87
Marktkapitalisierung:
$4.38B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
13.62
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
+1.61%
1M Leistung:
-8.40%
6M Leistung:
-15.79%
1J Leistung:
-1.15%
1-Tages-Spanne:
$26.30
$26.68
1-Wochen-Bereich:
$25.71
$28.67
52-Wochen-Spanne:
$25.56
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
26.55 | 4.37B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
What are the technical indicators suggesting about Alkermes plcSwing Trade Forecasts For Smart Trading - jammulinksnews.com
How strong is Alkermes plc company’s balance sheetExpert Picks Report For Fast Growth - jammulinksnews.com
Alkermes shares climb 5% following Q2 earnings and revenue beat - MSN
(07/31/25) ALKS: Positive Narcolepsy Drug Trial Puts this Biotech Name in F - moneyshow.com
Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances - MSN
Alkermes: A More Than Solid Quarter (NASDAQ:ALKS) - Seeking Alpha
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - Barchart.com
Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript - Insider Monkey
Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS) - MarketBeat
Alkermes Beat Expectations With A Strong Second Quarter - Finimize
Schizophrenia Drugs Market Exclusive Report with Detailed - openPR.com
Alkermes PLC (ALKS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Alkermes Reports Strong Q2 2025 Financial Results - TipRanks
Trading Bots Trigger Alerts on Alkermes plc ActivityDaily Smart Money Movement Monitor Activated - metal.it
Multi Factor Analysis Ranks Alkermes plc as Strong BuyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Alkermes Earnings Call: Strong Growth and Promising Trials - TipRanks
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire
Alkermes: Q2 Earnings Snapshot - Stamford Advocate
Alkermes price target lowered to $33 from $35 at BofA - TipRanks
Why Alkermes plc stock attracts strong analyst attentionScalable Portfolio Growth Suggestions Released - metal.it
Alkermes Q2 2025 Earnings Call Transcript - MarketBeat
Published on: 2025-07-29 17:34:19 - metal.it
Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Alkermes plc. SEC 10-Q Report - TradingView
Alkermes Q2 Sales Up 14 Percent - The Globe and Mail
Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Alkermes Q2 Earnings Exceed Expectations with Impressive Financial PerformanceNews and Statistics - IndexBox
Alkermes reports Q2 EPS 52c, consensus 38c - TipRanks
Alkermes shares rise 5% as Q2 earnings, revenue beat expectations By Investing.com - Investing.com Nigeria
Alkermes Plc earnings beat by $0.16, revenue topped estimates - Investing.com Australia
Alkermes plc Reports Second Quarter 2025 Financial Results - PR Newswire
RSI and MACD Indicate Shift in Alkermes plc SentimentStock Selection With High Accuracy Based on Models - metal.it
Alkermes plc Forms Double Bottom Pattern — Eyes on BreakoutInvestment Strategy With Predictable Gains Outlined - metal.it
Does Alkermes plc stock perform well during market downturnsEntry Signal Watchlist With High Returns - jammulinksnews.com
Federal Circuit Finds No Jurisdiction Over Patent Royalty Row, Transfers Case - Law360
Alkermes PLC (ALKS) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Published on: 2025-07-28 13:54:56 - metal.it
Is Alkermes plc stock overvalued or undervaluedAchieve consistent profits with expert advice - jammulinksnews.com
Should I hold or sell Alkermes plc stock in 2025Identify breakout stocks before they peak - jammulinksnews.com
What are analysts’ price targets for Alkermes plc in the next 12 monthsFree Market Volatility Navigation Tips - jammulinksnews.com
Is Alkermes plc Stock Overbought or Oversold RSI Indicator AnalysisCapital Efficient Investment Tips - metal.it
How does Alkermes plc generate profit in a changing economyUnlock exclusive stock analysis for investors - jammulinksnews.com
What catalysts could drive Alkermes plc stock higher in 2025Phenomenal trading returns - jammulinksnews.com
Is Alkermes plc a growth stock or a value stockUnlock steady growth with low-risk stocks - jammulinksnews.com
What drives Alkermes plc stock priceSuperior capital gains - Autocar Professional
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alkermes Plc-Aktie (ALKS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nichols Christian Todd | SVP, Chief Commercial Officer |
Jun 10 '25 |
Sale |
31.09 |
3,334 |
103,654 |
86,208 |
0.87%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):